Clopidogrel
Product Images NDC 58118-0357

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 58118-0357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (7c96b52e 99c9 4b70 B467 3d00bbc58acf 01)

Chemical structure of clopidogrel bisulfate showing the bicyclic core with a thiophene ring, a chlorophenyl group, and ester functional groups, consistent with the active ingredient clopidogrel. The presence of H2SO4 indicates the bisulfate salt form.*

FDA Label Image

Fig1 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 02)

A chart titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel Bisulfate 75 mg Alone or with Proton Pump Inhibitors (PPIs).' It shows the effect of co-administered PPIs (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) on active metabolite AUC, with mean values and 90% confidence intervals plotted relative to clopidogrel bisulfate administered alone. The x-axis represents change relative to clopidogrel bisulfate alone from 0.4 to 1.4.*

FDA Label Image

Fig2 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 03)

A line chart comparing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between placebo (+ aspirin) and clopidogrel bisulfate (+ aspirin) groups from the CURE study. The chart shows lower event rates in the clopidogrel bisulfate group, with a statistical significance of P=0.00009.*

FDA Label Image

Fig3 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 04)

A forest plot showing hazard ratios for patient baseline characteristics and on-study concomitant medications/interventions in the CURE study comparing Clopidogrel Bisulfate plus aspirin versus placebo plus aspirin. The chart includes various patient groups by diagnosis, age, gender, race, cardiac enzyme levels, previous myocardial infarction or stroke, and different concomitant therapies. Each category shows percent event rates and confidence intervals for hazard ratios favoring Clopidogrel or placebo.*

FDA Label Image

Fig4 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 05)

A line graph showing cumulative event rates for death in the COMMIT Study comparing Clopidogrel versus placebo over 28 days. The y-axis represents the percentage dead before first discharge, rising to about 8-9%, while the x-axis shows days since randomization. The graph includes data points for deaths and a noted 7% proportional risk reduction for Clopidogrel with p = 0.03. A footnote states all treated patients received aspirin.*

FDA Label Image

Fig5 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 06)

A Kaplan-Meier cumulative event rate graph comparing Clopidogrel and placebo in the COMMIT study. The y-axis shows the percentage of patients with death, re-infarction, or stroke before first discharge, and the x-axis shows days since randomization up to 28 days. Clopidogrel shows a lower event rate (9.2%) compared to placebo (10.1%), indicating a 9% proportional risk reduction with statistical significance (p=0.002).*

FDA Label Image

Fig6 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 07)

A forest plot illustrating the effects of adding Clopidogrel Bisulfate to aspirin on the combined primary endpoint across baseline and medication subgroups in the COMMIT Study. The chart compares event percentages, odds ratios with confidence intervals for Clopidogrel versus placebo, and tests for heterogeneity across categories such as sex, age, hours since onset, blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation.*

FDA Label Image

Fig7 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 08)

A forest plot chart titled 'Effects of Adding Clopidogrel Bisulfate to Aspirin in the Non-Prespecified Subgroups in the COMMIT Study.' It displays event percentages for Clopidogrel and Placebo groups across categories such as Killip class, Previous MI, and Infarct location with corresponding odds ratios, confidence intervals, and heterogeneity statistics indicating proportional reduction and p-values.*

FDA Label Image

Fig8 (7c96b52e 99c9 4b70 B467 3d00bbc58acf 09)

A line chart titled 'Fatal or Non-Fatal Vascular Events in the CAPRIE Study,' showing cumulative event rate (%) over 36 months of follow-up. Two lines compare aspirin and clopidogrel bisulfate, illustrating vascular event rates over time with a noted p-value of 0.045 indicating statistical analysis.*

FDA Label Image

Clopidogrel 75mg

Label for Clopidogrel 75mg Tablets by Clinical Solutions Wholesale. The package contains 30 tablets. Includes manufacturer NDC 65862-0357-90 and lot number SAMPLE123. Manufactured by Aubornido Pharma Limited, East Windsor, NJ, USA. Provides product NDC 58118-0357-8, GTIN 00358118035781, and batch number SAMPLE456.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.